Beclometasone inhaler used to treat pyoderma gangrenosum

Chriba, M.; Skellett, A. M.; Levell, N. J.

doi:10.1111/j.1365-2230.2009.03413.x

Cited by 12 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three were on 5‐ASA and steroids at PG onset, two did not respond to increased steroid dose as first‐line therapy, but responded to second‐line therapy with leucocytapheresis ( n = 1) or infliximab ( n = 1) . However, topical beclamethasone was effective in one case as first‐line therapy …”

Section: Resultsmentioning

confidence: 98%

“…Of them, only a single case achieved complete healing in 4 weeks (8%) and the other two had a steroid‐dependent response, requiring additional therapy with infliximab or topical tacrolimus . Topical inhaler beclamethasone was effective as monotherapy in a single case with complete healing in 4 weeks …”

Section: Resultsmentioning

confidence: 99%

“…Of the 17 patients on no therapy at PG onset, 16 healed, seven with first‐line therapy (topical/oral steroids ± dapsone, mesalazine (mesalamine), steroids + ciclosporin, steroid + 5‐ASA). Ten required a second‐line therapy, with nine responding.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Agarwal

Andrews

2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…[2930] Applications of beclomethasone inhaler 4 puffs to the peristomal PG have been reported to be successful. [31] Phenytoin sodium 2% solution has also been reported to be beneficial. [32] Hyperbaric oxygen therapy is thought to benefit PG elevating oxygen tension in the ulcers either through the greater arterial oxygen supplied to the capillary bed or through the local delivery of oxygen to the ulcer surface.…”

Section: Etiology and Pathogenesismentioning

confidence: 99%

Pyoderma gangrenosum: An update

Bhat

2012

Indian Dermatol Online J

164

104

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an uncommon, distinctive cutaneous ulceration which is usually idiopathic, but may be associated with many systemic disorders. The etipathogenesis of of PG is still not well understood. Clinically it is classified into ulcerative, pustular, bullous and vegetative types. A few atypical and rare variants have also been described. The diagnosis mainly depends on the recognition of evolving clinical features as investigations only assist in the diagnosis. In view of this a few criteria have been proposed for the diagnosis of PG. the treatment mainly consists of corticosteroids and immunosuppressive agents. A few new agents have also been tried in the management.

show abstract

“…Recently, inhaled corticosteroids were used with success in a case of peristomal PG refractory to other treatments. 21 Ciclosporin A, a calcineurin antagonist causing inhibition of T-lymphocyte activation, is the most widely used steroid alternative. Clinical improvement can be seen within weeks, with complete healing often within three months; a maintenance dose may be required.…”

Section: Treatmentmentioning

confidence: 99%

Management of pyoderma gangrenosum

Teagle

Hargest

2014

J R Soc Med

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an uncommon ulcerative skin disease often associated with underlying systemic diseases. Its pathogenesis is unknown, although immune pathways have been implicated. Targeted therapy is therefore lacking and currently treatment is largely empirical and consists of corticosteroids and ciclosporin first line. This paper reviews the current and emerging knowledge about PG. PG occurs with an incidence of 3–10 per million per year. The ulcers are exquisitely painful and characteristically have a necrotic centre with irregular overhanging bluish borders. Around half of cases are associated with underlying systemic disease, most commonly inflammatory bowel disease, rheumatoid arthritis and haematological malignancies; the remaining cases are idiopathic. The pathogenesis is unknown, but the most widely supported theory is immunological, and biopsies of lesions show a predominantly neutrophilic infiltrate. Several aberrant immune processes have been described, with neutrophils and their recruitment to sites of inflammation by cytokines taking an apparently important role. Topical and systemic therapies are both vital aspects of treatment, and in recent years, immune modulators have been used with increasing success, with an emerging role for anti-tumour necrosis factor alpha agents such as the monoclonal antibody infliximab. Although uncommon, PG causes significant morbidity to those it affects. Further research is needed into the disease pathogenesis, and adequate targeted treatment.

show abstract

Beclometasone inhaler used to treat pyoderma gangrenosum

Abstract: Pyoderma gangrenosum (PG) is a neutrophilic dermatosis, often associated with underlying systemic disease. We report the use of a corticosteroid inhaler to successfully treat peristomal PG.

Cited by 12 publications

References 3 publications

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy

Pyoderma gangrenosum: An update

Management of pyoderma gangrenosum

Contact Info

Product

Resources

About